227 related articles for article (PubMed ID: 38070112)
1. Hypoxic 3D Tumor Model for Evaluating of CAR-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract][Full Text] [Related]
2. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K
Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
4. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
5. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321
[TBL] [Abstract][Full Text] [Related]
7. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
8. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
9. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
10. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
11. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming.
Li H; Yang X; Wang Z; She W; Liu Y; Huang L; Jiang P
ACS Nano; 2023 Jun; 17(12):11749-11763. PubMed ID: 37319120
[TBL] [Abstract][Full Text] [Related]
12. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
14. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolism to improve CAR-T cells therapeutic efficacy.
Liu S; Zhao Y; Gao Y; Li F; Zhang Y
Chin Med J (Engl); 2024 Apr; 137(8):909-920. PubMed ID: 38501360
[TBL] [Abstract][Full Text] [Related]
16. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Crit Rev Biotechnol; 2022 Nov; 42(7):1079-1098. PubMed ID: 34957875
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic strategies to boost CAR TÂ cell therapy.
Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
20. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]